Endothelial function: Ready for prime time?

Canadian Journal of Cardiology

Volumn 20, Issue 13, 2004, Pages 1335-1339

  Verma, Subodh ^a,b,c   Szmitko, Paul E ^a   Anderson, Todd J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Atherosclerosis; Biomarker; C reactive protein; Endothelial function; Endothelium

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CD40 LIGAND; COLLAGEN; CORIOLIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PADGEM PROTEIN; PHOSPHOLIPASE A2; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOCRINE EFFECT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; ECHOGRAPHY; ENDOTHELIUM CELL; HEART INFARCTION; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; LEUKOCYTE ADHERENCE; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL CIRCULATION; PREDICTION; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STRESS, MECHANICAL; VASCULAR RESISTANCE;

EID: 10644268600     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002;105:546-9.
2. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
3. Verma S, Maitland A, Weisel RD, et al. Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg 2002;123:1074-83.
4. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002;105:2981-5.
5. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
6. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothetial dysfunction of the coronary microvascutature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
7. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.
8. Corretti MC, Anderson TJ, Benjamin EJ, et al; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65 (Erratum in 2002;39:1082).
9. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001;104:2879-82.
10. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.
11. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell inflammation: Part I. Circulation 2003;108:1917-23.
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
15. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
16. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
17. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4 (Erratum in 2001;104:1992).
18. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
19. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001;103:1194-7.
20. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-90.
21. Verma S, Wang CH, Weisel RD, et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: Reversal with rosiglitazone. J Mol Cell Cardiol 2003;35:417-9.
22. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67.
23. Yeh ET, Willerson JT. Coming of age of C-reactive protein: Using inflammation markers in cardiology. Circulation 2003;107:370-1.
24. Venugopal SK, Devaraj S, Yuhanna I, Shaul F, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
25. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis, Circulation 2003;107:398-404.
26. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-5.
27. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55.
28. Verma S, Szmitko PE, Yeh ET. C-reactive protein: Structure affects function. Circulation 2004;109:1914-7.
29. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
30. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
31. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996;93:457-62.
32. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
33. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
34. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
35. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
36. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8 (Erratum in 2003;108:500).
37. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: A study of women with chest pain and normal coronary angiograms. Circulation 2004;109:2518-23.
38. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-10.
39. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study. Circulation 2002;105:1567-72.
40. Anderson TJ, Roberts AC, Hildebrand K, et al. The fate of endothelial function testing: Rationale and design of the Firefighters And Their Endothelium (FATE) Study. Can J Cardiol 2003;19:61-6.
41. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. JAMA 2001;285:2481-5.
42. Brister SJ, Buchanan MR, Effects of linoleic acid and/or marine fish oil supplements on vessel wall thromboresistance in patients undergoing cardiac surgery. Adv Exp Med Biol 1997;423:275-8.
43. Varghese R, Brister SJ, Buchanan MR. Plasma 13-HODE levels, cardiovascular disease (CAD) severity and thrombotic risk in patients undergoing coronary artery bypass grafting (CABG). Can J Cardiol 2001;17(Suppl C):435. (Abst)
44. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003;108:2041-8.
45. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: New hope for a broken heart. Circulation 2003;107:3093-100.
46. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
47. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-7.